Careers  |  Sign In  |  Register  |   Twitter

Diabetes Drug Trial Halted Due to Safety Concerns

An article in Bloomberg News reports that Roche has announced it is halting a trial for the drug aleglitazar for type-2 diabetes due to “concerns about the drug’s safety and effectiveness.” Aleglitazar is thought to affect how fat and sugar are absorbed in the body by affecting the PPAR receptor protein. However, the drug was shown to be associated with negative side effects such as heart and kidney failure as well as bone fractures.

Read the article published by Bloomberg News.